Status:
UNKNOWN
Application Value of CEUS Li-RADS in Hepatic Focal Lesions in Patients With Non-high Risk Factors for HCC
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborating Sponsors:
Tianjin Third Central Hospital
Sichuan Provincial People's Hospital
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
Currently, there are few studies on the diagnostic ability of CEUS-LI-RADS in patients with non-high risk factors for liver nodules. Whether this classification is applicable to such patients remains ...
Detailed Description
According to the latest epidemiological survey in 2018, primary liver cancer is the sixth most common cancer in the world. Among these, hepatocellular carcinoma is the most common type of liver cancer...
Eligibility Criteria
Inclusion
- The patient showed focal liver lesions on routine ultrasound examination.
- Non-HCC high-risk patients (hepatitis B, cirrhosis)
Exclusion
- High-risk patients with HCC (hepatitis B, cirrhosis);
- Patients with solid liver tumors could not be found by conventional imaging;
- Patients who do not sign informed consent;
Key Trial Info
Start Date :
January 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04920214
Start Date
January 1 2021
End Date
December 31 2023
Last Update
July 15 2021
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Hospital
Beijing, Beijing Municipality, China, 100000
2
Fujian Cancer Hospital
Fuzhou, Fujian, China, 350000
3
Shengjing Hospital
Shenyang, Liaoning, China, 110000
4
General Hospital of Ningxia Medical University
Yinchuan, Ningxia, China, 750000